Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+/HER2-metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial

被引：0
|
作者：
Gustavo, Federico
Todo, Rojo
Meier, Lara
Martinez, Maria Teresa
Lopez, Maria Esteban
Paris, Lorena
O'Connor, Miriam
Merino, Luis De la Cruz
Santaballa, Ana
Martinez-Janez, Noelia
Anton, Fernando Moreno
Fernandez, Isaura
Keane, Maccon
Garcia-Palomo, Andres
Starus, Anna
Portela, Marta
Herranz, Jesus
Caballero, Rosalia
Jones, Frederick
Albanell, Joan
机构：
[1] Hosp Univ Fdn Jimenez Diaz, Barcelona, Spain
[2] CIBERONC ISCCIII, Barcelona, Spain
[3] GEICAM Spanish Breast Canc Grp, Barcelona, Spain
[4] Sysmex Inostics Gmbh, Hamburg, Germany
[5] Hosp Clin Univ Valencia, INCLIVA, Valencia, Spain
[6] GEICAM Spanish Breast Canc Grp, Valencia, Spain
[7] Sysmex Inostics Inc, Hamburg, Germany
[8] Ctr Oncol Galicia, La Coruna, Spain
[9] GEICAM Spanish Breast Canc Grp, La Coruna, Spain
[10] Univ Hosp Waterford Canc Trials Ireland, Waterford, Ireland
[11] Univ Seville, Hosp Univ Virgen Macarena, Dept Med, Med Oncol, Seville, Spain
[12] Hosp Univ & Politecn La Fe, Dept Med Oncol, Valencia, Spain
[13] Raman y Cajal Univ Hosp, Inst Ramon y Cajal Invest Sanitaria IRYCIS, Madrid, Spain
[14] Hosp Clin Univ San Carlos, Madrid, Spain
[15] GEICAM Spanish Breast Canc Grp, Madrid, Spain
[16] Hosp Alvaro Cunqueiro, Vigo, Spain
[17] GEICAM Spanish Breast Canc Grp, Vigo, Spain
[18] Hopsital Univ Son Espases, Palma de Mallorca, Spain
[19] GEICAM Spanish Breast Canc Grp, Palma de Mallorca, Spain
[20] Galway Univ Hosp, CIBERONC ISCIII, Galway, Ireland
[21] Complejo Asistencial Univ Leon, Leon, Spain
[22] GEICAM Spanish Breast Canc Grp, Leon, Spain
[23] Sysmex Inostics Inc, Baltimore, MD USA
[24] GEICAM Spanish Breast Canc Grp, Madrid, Spain
[25] Hosp Mar, CIBERONC ISCIII, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1029
引用
收藏
页数：1
相关论文
共 34 条
  • [31] INAVO121: Phase III study of inavolisib (INAVO) plus fulvestrant (FUL) vs. alpelisib (ALP) plus FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2-) PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC)
    Juric, Dejan
    Kalinsky, Kevin
    Im, Seock-Ah
    Ciruelos, Eva M.
    Bianchini, Giampaolo
    Barrios, Carlos H.
    Jacot, William
    Schmid, Peter
    Loi, Sherene
    Rugo, Hope S.
    Craine, Veronica
    Hutchinson, Katherine E.
    Flechais, Aulde
    Thanopoulou, Eirini
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] INAVO121: Phase III study of inavolisib (INAVO) plus fulvestrant (FUL) vs. alpelisib (ALP) plus FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2-), PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC)
    Juric, Dejan
    Kalinsky, Kevin
    Im, Seock-Ah
    Ciruelos, Eva
    Bianchini, Giampaolo
    Barrios, Carlos H., Sr.
    Jacot, William
    Schmid, Peter
    Loi, Sherene
    Rugo, Hope S.
    Craine, Veronica
    Hutchinson, Katherine E.
    Flechais, Aulde
    Thanopoulou, Eirini
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Olivera, Mafalda
    Jhaveri, Komal
    Juric, Dejan
    Bedard, Philippe L.
    Cervantes, Andres
    Gambardella, Valentina
    Hamilton, Erika
    Italiano, Antoine
    Kalinsky, Kevin
    Krop, Ian E.
    Schmid, Peter
    Turner, Nicolas
    Varga, Andrea
    Lei, Guiyuan
    Royer-Joo, Stephanie
    Thomas, Piia
    Schutzman, Jennifer L.
    Saura, Cristina
    CANCER RESEARCH, 2021, 81 (04)
  • [34] GeparPiPPaEine randomisierte, offene Phase-II-Studie zum Vergleich einer neoadjuvanten Behandlung mit einer endokrinen Therapie in Kombination mit Trastuzumab und Pertuzumab ± PI3K-Inhibitor Inavolisib bei Patienten mit Hormonrezeptor-positivem, HER2-positivem primärem Mammakarzinom und einer PIK3CA-MutationGeparPiPPaA randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab and pertuzumab with/without the PI3K inhibitor inavolisib in patients with HR+/HER2+ primary breast cancer and a PIK3CA mutation
    Mattea Reinisch
    Sabine Seiler
    Johannes Holtschmidt
    Sibylle Loibl
    Forum, 2024, 39 (3) : 227 - 231
1234